CALGB 90202: A randomized double-blind, placebo-controlled phase III study of early vs standard zoledronic acid to prevent skeletal-related events in men with prostate cancer metastatic to the bone

Clinical Advances in Hematology and Oncology

Volumn 4, Issue 12, 2006, Pages 897-898

  Smith, Matthew R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PLACEBO; ZOLEDRONIC ACID;

ARTICLE; BONE METASTASIS; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL RESEARCH; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG RESPONSE; EARLY INTERVENTION; INTERMETHOD COMPARISON; OPEN STUDY; OVERALL SURVIVAL; PROSTATE CANCER; RISK REDUCTION; THERAPY DELAY;

EID: 33846410285     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (2)

1. Saad F, Gleason M, Murray R, et al. Zoledronic acid reduces skeletal complications in patients with hormone-refractory prostate carcinoma metastatic to bone: a randomized placebo-controlled trial. J Natl Cancer Inst. 2002;94:1458-1468.
2. Dearnaley DP, Sydes MR. Preliminary evidence that oral clodronate delays symptomatic progression of bone metastases from prostate cancer: first results of the MRC Pr05 trial. Proc Am Soc Clin Oncol. 2001;20:174a.